Chong Kun Dang Pharmaceutical (185750.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7185750007

Price
62,700.00 KRW
Market cap
826.14 bn KRW
P/E (2025)
10.66
P/S (2025)
0.49
Dividend yield
0.80 %
Net margin
4.58 %
Return on equity (ROE)
7.72 %
Return on assets (ROA)
4.31 %

Chong Kun Dang Pharmaceutical financials

Fiscal year20242025
Revenue1.59 tn KRW1.69 tn KRW
Gross profit532.61 bn KRW526.38 bn KRW
Operating income99.46 bn KRW80.57 bn KRW
EBIT110.33 bn KRW88.35 bn KRW
Net income109.07 bn KRW77.51 bn KRW
Diluted EPS – continuing operations8,679.16 KRW5,882.52 KRW

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Chong Kun Dang Pharmaceutical

Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.